| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.9M | — | +1050.3% |
| SG&A Expense | $14.0M | — | — |
| Operating Income | -$21.8M | — | — |
| Income Tax | $0 | — | — |
| Net Income | -$21.3M | — | — |
| EPS (Basic) | -$0.39 | — | — |
| EPS (Diluted) | -$0.39 | — | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $84.8M | +257.4% | — |
| Current Assets | $91.8M | +275.7% | — |
| Total Assets | $92.0M | +272.7% | — |
| Current Liabilities | $3.9M | +60.3% | +2188.2% |
| Total Liabilities | $3.9M | +62.1% | +2214.0% |
| Stockholders' Equity | $88.1M | +295.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.0M | — | — |
| Capital Expenditures | $53K | — | +252.6% |
| Investing Cash Flow | -$53K | — | -252.6% |
| Financing Cash Flow | $75.1M | — | +8630.2% |
| Free Cash Flow | -$14.1M | — | — |
| — |